TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating Working Memory Deficits in Patients With Schizophrenia Using Repetitive Transcranial Magnetic Stimulation (rTMS)
Brief Summary: Deficits in working memory (WM) performance are the most significant cognitive impairments in schizophrenia (SCZ). It has also been shown that WM performance is contingent on the cortex synchronization, a process that relies on brain inhibition. Repetitive Transcranial Magnetic Stimulation (rTMS) has been demonstrated as an effective treatment for patients with SCZ and has been shown to increase brain inhibition and improve cognitive performance. In this study the investigators intend to:

* evaluate rTMS as a treatment for WM deficits in SCZ
* evaluate rTMS as a method to increase WM performance in healthy individuals
* determine if improvements in WM performance are related to enhanced synchronization of brain networks
* determine whether genetic polymorphisms predict cortical function and treatment response
* evaluate the influence of rTMS treatment on brain structure.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Repetitive transcranial magnetic stimulation | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Other: Sham repetitive transcranial magnetic stimulation | Intervention Type: OTHER; Name: Repetitive transcranial magnetic stimulation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Sham repetitive transcranial magnetic stimulation; Assigned to Arm(s): 2
B: Arm Label: Active rTMS; Type: ACTIVE_COMPARATOR; Interventions: Device: repetitive Transcranial Magnetic Stimulation | Arm Label: Sham rTMS; Type: SHAM_COMPARATOR; Interventions: Device: repetitive Transcranial Magnetic Stimulation | Intervention Type: DEVICE; Name: repetitive Transcranial Magnetic Stimulation; Assigned to Arm(s): Active rTMS, Sham rTMS
C: Arm Label: Real TMS; Type: ACTIVE_COMPARATOR; Interventions: Device: DEEP TMS H1 coil | Arm Label: Sham & real TMS; Type: PLACEBO_COMPARATOR; Interventions: Device: Deep H1 coil TMS | Intervention Type: DEVICE; Name: DEEP TMS H1 coil; Assigned to Arm(s): Real TMS | Intervention Type: DEVICE; Name: Deep H1 coil TMS; Assigned to Arm(s): Sham & real TMS
D: Arm Label: rTMS; Type: SHAM_COMPARATOR; Interventions: Procedure: rTMS, "repetitive transcranial magnetic stimulation", Other: rTMS | Intervention Type: PROCEDURE; Name: rTMS, "repetitive transcranial magnetic stimulation"; Assigned to Arm(s): rTMS | Intervention Type: OTHER; Name: rTMS; Assigned to Arm(s): rTMS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Escalating Dose Study to Assess the Safety, Tolerability and Dose-range Finding of a Single Intrathecal Dose of ISIS 396443 in Patients With Spinal Muscular Atrophy
Brief Summary: This objectives of this study are to evaluate the safety, tolerability, and pharmacokinetics of a single dose of nusinersen (ISIS 396443) administered intrathecally to participants with Spinal Muscular Atrophy (SMA).


Options:
A: Arm Label: Cohort 1 (n=6); Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Cohort 2 (n=6); Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Cohort 3 (n=6); Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Cohort 4 (n=10); Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): Cohort 1 (n=6), Cohort 2 (n=6), Cohort 3 (n=6), Cohort 4 (n=10)
B: Arm Label: Nusinersen; Type: EXPERIMENTAL; Interventions: Drug: Nusinersen | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: DRUG; Name: Nusinersen; Assigned to Arm(s): Nusinersen | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham procedure
C: Arm Label: Nusinersen 6 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Nusinersen 12 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): Nusinersen 12 mg, Nusinersen 6 mg
D: Intervention Type: DRUG; Name: Valproic Acid; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Group-based, Cognitive-behavioural Intervention With Former Child Soldiers and Other War-affected Children in the Democratic Republic of Congo: A Randomised Controlled Trial.
Brief Summary: The purpose of this study is to evaluate, in a randomised control trial (RCT), the effectiveness of group-based, trauma-focused Cognitive Behaviour Therapy (TF-CBT) in reducing psychological distress in former child soldiers and other war-affected children in the Democratic Republic of Congo (DRC).


Options:
A: Arm Label: Waitlist-Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Common Elements Treatment Approach; Type: EXPERIMENTAL; Interventions: Behavioral: Common Elements Treatment Approach | Intervention Type: BEHAVIORAL; Name: Common Elements Treatment Approach; Assigned to Arm(s): Common Elements Treatment Approach
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: NET | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: NET; Assigned to Arm(s): A
C: Arm Label: IPT arm; Type: EXPERIMENTAL; Interventions: Behavioral: interpersonal psychotherapy for groups | Arm Label: CP arm; Type: EXPERIMENTAL; Interventions: Behavioral: creative play therapy | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: interpersonal psychotherapy for groups; Assigned to Arm(s): IPT arm | Intervention Type: BEHAVIORAL; Name: creative play therapy; Assigned to Arm(s): CP arm
D: Arm Label: TF-CBT; Type: EXPERIMENTAL; Interventions: Behavioral: TF-CBT | Arm Label: Waiting List control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: TF-CBT; Assigned to Arm(s): TF-CBT

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Group-based, Cognitive-behavioural Intervention With Former Child Soldiers and Other War-affected Children in the Democratic Republic of Congo: A Randomised Controlled Trial.
Brief Summary: The purpose of this study is to evaluate, in a randomised control trial (RCT), the effectiveness of group-based, trauma-focused Cognitive Behaviour Therapy (TF-CBT) in reducing psychological distress in former child soldiers and other war-affected children in the Democratic Republic of Congo (DRC).


Options:
A: Arm Label: TF-CBT; Type: EXPERIMENTAL; Interventions: Behavioral: TF-CBT | Arm Label: Waiting List control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: TF-CBT; Assigned to Arm(s): TF-CBT
B: Intervention Type: BEHAVIORAL; Name: Trauma and Grief Component Therapy for Adolescents (Group Version); Assigned to Arm(s): N/A
C: Arm Label: Family-Focused Psychosocial Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention; Assigned to Arm(s): Family-Focused Psychosocial Intervention
D: Arm Label: Trauma-Focused Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma-Focused Cognitive Behavioral Therapy | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trauma-Focused Cognitive Behavioral Therapy; Assigned to Arm(s): Trauma-Focused Cognitive Behavioral Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Group-based, Cognitive-behavioural Intervention With Former Child Soldiers and Other War-affected Children in the Democratic Republic of Congo: A Randomised Controlled Trial.
Brief Summary: The purpose of this study is to evaluate, in a randomised control trial (RCT), the effectiveness of group-based, trauma-focused Cognitive Behaviour Therapy (TF-CBT) in reducing psychological distress in former child soldiers and other war-affected children in the Democratic Republic of Congo (DRC).


Options:
A: Arm Label: BF-CBT and group physiotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: BF-CBT and group physiotherapy | Arm Label: Waiting list; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BF-CBT and group physiotherapy | Intervention Type: BEHAVIORAL; Name: BF-CBT and group physiotherapy; Assigned to Arm(s): BF-CBT and group physiotherapy, Waiting list
B: Arm Label: NET; Type: EXPERIMENTAL; Interventions: Behavioral: Narrative Exposure Therapy | Arm Label: AC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Academic Counseling | Arm Label: WL; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Narrative Exposure Therapy; Assigned to Arm(s): NET | Intervention Type: BEHAVIORAL; Name: Academic Counseling; Assigned to Arm(s): AC
C: Arm Label: TF-CBT; Type: EXPERIMENTAL; Interventions: Behavioral: TF-CBT | Arm Label: Waiting List control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: TF-CBT; Assigned to Arm(s): TF-CBT
D: Arm Label: treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: treatment as usual | Arm Label: interpersonal psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: interpersonal psychotherapy | Intervention Type: BEHAVIORAL; Name: interpersonal psychotherapy; Assigned to Arm(s): interpersonal psychotherapy | Intervention Type: BEHAVIORAL; Name: treatment as usual; Assigned to Arm(s): treatment as usual

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Role of Oral Nystatin Prophylaxis in ICU Surgical/Trauma Patients
Brief Summary: Purpose. Oral chemoprophylaxis has been advocated to reduce the incidence of Candida colonization and infection. However, Candida prophylaxis in intensive care unit (ICU) is still a matter of debate.

Methods. Randomized, single-center trial studying single drug (nystatin) versus control in surgical ICU patients. Multiple-site testing for fungi were performed in each patient at ICU admission (T0) and subsequently every 3 days (T3, T6, T9...). The primary evaluation criterion was the time course of colonization index (CI) during ICU stay.


Options:
A: Arm Label: 1 prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Caspofungin | Arm Label: 2 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Intervention Type: DRUG; Name: Caspofungin; Assigned to Arm(s): 1 prophylaxis | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): 2 placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal Saline | Arm Label: Antifungal; Type: ACTIVE_COMPARATOR; Interventions: Drug: anidulafungin | Intervention Type: OTHER; Name: Normal Saline; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: anidulafungin; Assigned to Arm(s): Antifungal
C: Arm Label: Nystatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nystatin | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nystatin | Intervention Type: DRUG; Name: Nystatin; Assigned to Arm(s): Control, Nystatin
D: Arm Label: Micafungin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Micafungin | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO | Intervention Type: DRUG; Name: Micafungin; Assigned to Arm(s): Micafungin | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): PLACEBO

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Dietary modification is of great essential for the prevention and treatment of type 2 diabetes mellitus. Common oat (Avena sativa L.) and its products showed a great potential benefits on NCDs including type 2 diabetes mellitus. But data about such effects of naked oat (Avena nuda L.) is still unavailable. The investigators aimed to examine the effects of organic naked oat with whole germ (ONOG) plus diet on patients with type 2 diabetes.

After a pre-study with healthy adults, a randomized, single-blinded, multi-arm parallel trial of 30 days would be carried out in adults of 50-65 years old with type 2 diabetes. Participants would be randomly assigned to one of the four following groups: usual care group (only basic health advice, no other interventions), diet group (systematic education, structured dietary), 50g-ONOG plus diet group (all the interventions of diet group plus replacement of 50g ONOG per day) and 100g-ONOG plus diet group. A regular follow-up for years would be carried out to predict the long-term effects of ONOG plus diet intervention on patients with type 2 diabetes.

The investigators hypothesized that ONOG combined with diet would have better effects on glycaemia and insulin resistance control in addition to those yielded by diet or usual care.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Brown rice/White rice | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Brown rice/White rice | Intervention Type: DIETARY_SUPPLEMENT; Name: Brown rice/White rice; Assigned to Arm(s): A, B
B: Arm Label: Wholegrain cereal oats; Type: EXPERIMENTAL; Interventions: Dietary Supplement: wholegrain cereals oats (WGO) | Arm Label: Non wholegrain cereals; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Non wholegrain cereals | Intervention Type: DIETARY_SUPPLEMENT; Name: wholegrain cereals oats (WGO); Assigned to Arm(s): Wholegrain cereal oats | Intervention Type: DIETARY_SUPPLEMENT; Name: Non wholegrain cereals; Assigned to Arm(s): Non wholegrain cereals
C: Arm Label: Refined grain; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Refined grain | Arm Label: Whole grain diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Whole grain diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Whole grain diet; Assigned to Arm(s): Whole grain diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Refined grain; Assigned to Arm(s): Refined grain
D: Arm Label: Usual care group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: diet group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 50g-ONOG plus diet group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: organic naked oat with whole germ (ONOG) | Arm Label: 100g-ONOG plus diet group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: organic naked oat with whole germ (ONOG) | Intervention Type: DIETARY_SUPPLEMENT; Name: organic naked oat with whole germ (ONOG); Assigned to Arm(s): 100g-ONOG plus diet group, 50g-ONOG plus diet group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glucomannn for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Randomized Double Blind Placebo Controlled Trial
Brief Summary: Background: Functional abdominal pain disorders (FAPD) are common in school-aged children; however, there is no reliable treatment.

Aim: To determine the efficacy and safety of glucomannan for treating FAPD in children.

Trial Setting: Department of Pediatrics, The Medical University of Warsaw.

Intervention: Patients will be enrolled in a double-blind, randomized controlled trial in which they will receive either glucomannan (10g) or placebo for 4 weeks.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus GG (probiotic ) | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus GG (probiotic ); Assigned to Arm(s): Probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Probiotics supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Glucomannan; Type: EXPERIMENTAL; Interventions: Drug: Glucomannan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Glucomannan; Assigned to Arm(s): Glucomannan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fiber; Type: EXPERIMENTAL; Interventions: Behavioral: Elimination Diet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Elimination Diet | Intervention Type: BEHAVIORAL; Name: Elimination Diet; Assigned to Arm(s): Fiber, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study
Brief Summary: Examine whether daily oral ingestion of a immunomodulatory mushroom extract (AndoSanTM) in patients with ulcerative colitis (UC) and Crohn's disease (CD), experience clinical, biochemical and genetical improvement in their disease.

A prospective randomised study comparing the mushroom extract with placebo.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Sargramostim (Leukine) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sargramostim (Leukine); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2
B: Arm Label: AndoSan; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: AndoSan | Arm Label: Sugar extract; Type: SHAM_COMPARATOR; Interventions: Dietary Supplement: Sugar Extract | Intervention Type: DIETARY_SUPPLEMENT; Name: AndoSan; Assigned to Arm(s): AndoSan | Intervention Type: DIETARY_SUPPLEMENT; Name: Sugar Extract; Assigned to Arm(s): Sugar extract
C: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducational programme, Other: Standard care | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard care | Intervention Type: BEHAVIORAL; Name: Psychoeducational programme; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Control group, Intervention group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B
Brief Summary: This study will examine the safety, pharmacokinetics and efficacy of rIX-FP for the control and prevention of bleeding episodes in subjects who have previously received factor replacement therapy for hemophilia B.


Options:
A: N/A
B: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): On-demand
C: Arm Label: SPK-9001; Type: EXPERIMENTAL; Interventions: Biological: SPK-9001 | Intervention Type: BIOLOGICAL; Name: SPK-9001; Assigned to Arm(s): SPK-9001
D: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Intervention Type: BIOLOGICAL; Name: rIX-FP; Assigned to Arm(s): On-demand, Prophylaxis

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B
Brief Summary: This study will examine the safety, pharmacokinetics and efficacy of rIX-FP for the control and prevention of bleeding episodes in subjects who have previously received factor replacement therapy for hemophilia B.


Options:
A: Arm Label: Group 1; Type: OTHER; Interventions: Genetic: Gene Transfer, Drug: scAAV2/8-LP1-hFIXco | Intervention Type: GENETIC; Name: Gene Transfer; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: scAAV2/8-LP1-hFIXco; Assigned to Arm(s): Group 1
B: N/A
C: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Intervention Type: BIOLOGICAL; Name: rIX-FP; Assigned to Arm(s): On-demand, Prophylaxis
D: Arm Label: Fixed Weekly Interval; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc), Drug: rFIX | Arm Label: Individualized Interval; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Arm Label: On Demand; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Arm Label: Surgery; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Intervention Type: DRUG; Name: Factor IX (rFIXFc); Assigned to Arm(s): Fixed Weekly Interval, Individualized Interval, On Demand, Surgery | Intervention Type: DRUG; Name: rFIX; Assigned to Arm(s): Fixed Weekly Interval

Answer: C